$CLVT

Cornick Kenneth L. purchased $1.7M of CLVT (indirect holdings)

Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · Cornick Kenneth L.
Published Aug 10, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLVT
Bullish
medium confidence
Mentioned
$CLVT
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLVTBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 900,000 shares (indirect holdings) at $1.8500 to $1.8600 per share, totaling $1.6715M, reported via Form 4 filed 2026-08-10.

02

Market read

Traders may treat the insider buy as a small sentiment input, but there is no accompanying fundamental update in the text.

03

What to watch

The filing notes no 10b5-1 plan, but it also provides no rationale for the purchase, and the trades occurred days before the filing, reducing immediacy.

Relevance 7/10Novelty 5/10Timing: Form 4 filed 2026-08-10 after trades dated 2026-08-06 to 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Clarivate PLC (CLVT).

Company-level read

Ticker impact

$CLVTBullishMedium confidence
Context

Clarivate PLC director Cornick Kenneth L. bought 900,000 shares in open-market trades for about $1.67M, filed as a Form 4 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is typically small and short-lived versus macro or company-specific fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and the transaction size is non-trivial, but the article provides no new company performance, outlook, or regulatory/contract event that would drive repricing.

Market effects

No sector-wide implications are disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect a change in fundamentals.

Key entities

  • CLARIVATE PLC

    Subject of the Form 4 insider transaction disclosure.

  • Cornick Kenneth L.

    Director who purchased 900,000 shares in open-market trades (indirect holdings).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Ex. 99.1 Q2 2026 Earnings Release 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile wit

$CLVTMedAI 8/10

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.